JAMA Neurology: Early Ocrelizumab Reduces Relapsing MS Disability at 10 Years
Patients who began continuous ocrelizumab treatment early in relapsing multiple sclerosis maintained a 24% lower hazard of confirmed disability progression at 10 years compared to those who switched after two years of initial interferon beta-1a exposure, according to research published October 5 in JAMA Neurology.
Key Clinical Takeaways:
- Data from the 10-year OPERA I and OPERA II extension trials confirmed durable benefits for patients with relapsing multiple sclerosis who started ocrelizumab early.
- Continuous early treatment reduced the hazard of needing a walking aid by 43% and lowered the 10-year relapse risk by 38%.
- Safety profiles remained stable over more than 10,800 patient-years of exposure, with serious infection rates remaining generally stable and malignancy rates matching general population levels.
Ten-Year OPERA Trial Findings and the Cost of Delaying Anti-CD20 Therapy
The long-term follow-up data evaluated 1,656 adults originally randomized in the double-blind phase of the OPERA I and II trials. Patients received either intravenous ocrelizumab at 600 mg every 24 weeks or subcutaneous interferon beta-1a at 44 µg three times per week for the initial two years. Following that phase, 1,325 individuals entered an open-label extension to receive ocrelizumab for up to eight additional years.
Among the cohort assigned to ocrelizumab from the outset, 82.2% remained free of disability progression confirmed for 48 weeks across the entire decade. Patients who spent the first two years on interferon beta-1a before switching faced a hazard ratio of 0.76.
Milestone Reached on Expanded Disability Status Scale Scores
Early continuous dosing altered the trajectory of physical independence across multiple scoring thresholds. Patients maintaining continuous ocrelizumab experienced a 34% lower hazard of reaching an Expanded Disability Status Scale score of 4.0, with 93.3% staying below that mark. For the more severe threshold of an EDSS score of 6.0, continuous treatment lowered the hazard by 43%. A total of 94.2% of early-start patients remained below this milestone.
Relapse activity dropped across the board during the decade-long observation. Over 10 years, 73.0% of the continuous ocrelizumab group remained free from relapse, contrasted with 63.2% of the group that delayed treatment by starting on interferon beta-1a. Investigators led by Stephen L. Hauser of the UCSF Weill Institute for Neurosciences noted that annual relapse rates declined steadily until approximately one out of 100 patients experienced a relapse in year 10.
Suppression of Magnetic Resonance Imaging Activity and Safety Analysis
Magnetic resonance imaging measures demonstrated near-complete suppression of disease activity that persisted throughout the follow-up window. Over the 10-year period, 58.6% of patients treated continuously with ocrelizumab showed no evidence of disease activity, compared to 38.0% of those who began on interferon. Safety evaluations encompassing 1,448 patients and more than 10,800 patient-years of exposure showed no cumulative toxicity signals.
Serious infections held steady at a rate of 1.8 per 100 patient-years. While mean immunoglobulin G levels decreased over time, 84.5% of patients maintained levels above the lower limit of normal, and prolonged exposure did not increase serious infection risk regardless of IgG status. Malignancy rates stayed aligned with those observed in the general population and external multiple sclerosis cohorts. F. Hoffmann-La Roche funded the research, and several study authors reported financial relationships with pharmaceutical companies.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.